James Reese Is Doing All He Can To Help TigerSwan Grow

TigerSwan offers private security services and operates in over 50 countries around the world with hundreds of employees. It is run by CEO and former military Lt. Colonel James Reese. The company is a service-disabled and veteran-owned company that works hard for the individuals and families that use its services. It is a small business but is hoping to continue to grow and to have the loyalty of many of its customers for years to come. James Reese takes the job of being CEO of the company seriously and says that he feels a lot of responsibility for those using its services.

TigerSwan helps veterans make the transition back to civilian life by employing them and that was part of the motivation behind the company being started. James Reese knew that he wanted to create a business of some kind after retiring from the military and he came up with the plan for TigerSwan in his friend’s kitchen. James Reese has tried to hire the best people for his company so that he can run it well. He says that it hasn’t been easy to make the transition from being a leader in the military to a business leader because he can’t afford all of the people that he wants working for him but he has tried to do his best to hire those he can afford.

James Reese knows what it takes to be a good leader and has always made it a priority to listen to others. He also knows that when he is a follower, he needs to be loyal to those he is following. He founded TigerSwan in 2008 and is a great problem-solver. James Reese has worked hard to make the transition from military to civilian and the team he built for TigerSwan has helped it succeed.

Connect with TigerSwan here https://www.facebook.com/TigerSwanNC/

Renovia and CEO Marc Beer Raise $42 Million

Renovia Inc., a medical technology startup, recently announced along with Chief Executive Officer and co-founder Marc Beer, that the company will move forward with plans to develop a series of new products designed to help people deal with disorders that affect their pelvic floor. This news follows the closing of the company’s $32 million Series B offering, in addition to their $10 million venture debt.


The company which is headquartered in Boston, Massachusetts, has a pipeline of products for the diagnosis and therapy of various pelvic floor disorders such as urinary incontinence, which many researchers believe to be affecting at least 250 million women across the globe. The company’s initial product, Leva, received approval from the Food and Drug Administration in April.


Renovia received financial backing early on from The Longwood Fund, an investment firm which is heavily focused on health care. Longwood also invested and the company’s Series B round offering which was led by the Missouri based Ascension Ventures and New York’s Perceptive Advisors. The funding the company received from the Series B will be utilized in the development and testing of four additional products designed to aid in the diagnosis and provide therapeutic treatment for pelvic floor disorders. One of these products is the next generation of the Leva device mentioned earlier.


The company’s CEO Marc Beer stated that the company was thrilled by the level of support they were receiving from many of the foremost healthcare financiers. The company was gratified to see these investors share the company’s vision of better ways to treat, diagnose, and increase the quality of life for the many millions of women suffering from pelvic floor disorders. He went on to say that the company will utilize innovation with their proprietary sensors to provide valuable data to customers they can use to help determine the best treatment options. He also believes this technology can be used to increase the understanding of disorders affecting the pelvic floor, and eventually reduce the cost of long-term health care.


Marc Beer learned a bachelor of science degree from the University of Miami, in Ohio. He serves as a member of the Miami University’s Business Advisory Council and previously served as a member of the Notre Dame Research and Commercialization Advisory Committee as well as the Research and Advisory Council for Graduate Studies.


Mr. Beer was previously the CEO of ViaCell, a company in the biotechnology sector that specializes in collecting, preserving, and developing stem cells derived from umbilical cord blood. He was the company’s leader from inception through a period of rapid growth and development. While he served as CEO of the company it continued to grow in size to over 300 employees. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer